tiprankstipranks
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
US Market
AMLX
Amylyx Pharmaceuticals Inc
RESEARCH TOOLSreports
Want to see AMLX full AI Analyst Report?

Amylyx Pharmaceuticals Inc (AMLX) Stock Forecast & Price Target

723 Followers
See the Price Targets and Ratings of:

AMLX Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Amylyx
Pharmaceuticals Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AMLX Stock 12 Month Forecast

Average Price Target

$43.00
▲(14.79% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Amylyx Pharmaceuticals Inc in the last 3 months. The average price target is $43.00 with a high forecast of $57.00 and a low forecast of $23.00. The average price target represents a 14.79% change from the last price of $37.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","33":"$33","58":"$58","20.5":"$20.5","45.5":"$45.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,20.5,33,45.5,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.81,35.59384615384616,37.37769230769231,39.16153846153846,40.94538461538462,42.72923076923077,44.51307692307692,46.29692307692308,48.080769230769235,49.864615384615384,51.64846153846154,53.43230769230769,55.216153846153844,{"y":57,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.81,34.51692307692308,35.223846153846154,35.93076923076923,36.63769230769231,37.34461538461539,38.05153846153846,38.75846153846154,39.465384615384615,40.17230769230769,40.87923076923077,41.58615384615385,42.293076923076924,{"y":43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.81,32.97846153846154,32.14692307692308,31.315384615384616,30.483846153846155,29.652307692307694,28.820769230769233,27.989230769230772,27.157692307692308,26.326153846153847,25.494615384615386,24.663076923076922,23.831538461538464,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.08,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.01,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.07,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.95,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.31,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.81,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$57.00Average Price Target$43.00Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on AMLX
Seamus Fernandez
Guggenheim
Guggenheim
$55→$57
Buy
52.16%
Upside
Assigned
08/26/26
Amylyx price target raised to $57 from $55 at GuggenheimAmylyx price target raised to $57 from $55 at Guggenheim
LifeSci Capital Analyst forecast on AMLX
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$24→$44
Buy
17.46%
Upside
Reiterated
08/22/26
Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital
H.C. Wainwright Analyst forecast on AMLX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$34→$55
Buy
46.82%
Upside
Reiterated
08/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mizuho Securities Analyst forecast on AMLX
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$30→$42
Buy
12.12%
Upside
Reiterated
08/19/26
Mizuho Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)
Citi Analyst forecast on AMLX
Geoff Meacham
Citi
Citi
$26→$32
Buy
-14.58%
Downside
Reiterated
08/19/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Insight Molecular Diagnostics (NASDAQ: IMDX) and Innovent Biologics (Other OTC: IVBXF)
Bank of America Securities Analyst forecast on AMLX
Jason Gerberry
Bank of America Securities
Bank of America Securities
$39
Buy
4.11%
Upside
Reiterated
08/18/26
Jason Gerberry Boosts Amylyx Price Target to $39 on Strong LUCIDITY Phase 3 Avexitide Data and $1.8B Peak Sales Outlook
TD Cowen Analyst forecast on AMLX
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/18/26
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Moderna (NASDAQ: MRNA) and Merck & Company (NYSE: MRK)
Stifel Nicolaus Analyst forecast on AMLX
James Condulis
Stifel Nicolaus
Stifel Nicolaus
―
Buy
―
Reiterated
08/18/26
Analysts' Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), BioMarin Pharmaceutical (BMRN)
Robert W. Baird Analyst forecast on AMLX
Christopher Chen
Robert W. Baird
Robert W. Baird
$28→$52
Buy
38.81%
Upside
Reiterated
08/18/26
Amylyx price target raised to $52 from $28 at BairdAmylyx price target raised to $52 from $28 at Baird
Goldman Sachs Analyst forecast on AMLX
Corinne Johnson
Goldman Sachs
Goldman Sachs
$22→$23
Buy
-38.60%
Downside
Reiterated
06/18/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and AbCellera Biologics (NASDAQ: ABCL)
Leerink Partners Analyst forecast on AMLX
Marc Goodman
Leerink Partners
Leerink Partners
$10→$20
Buy
-46.61%
Downside
Reiterated
10/07/25
Leerink Partners Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on AMLX
Seamus Fernandez
Guggenheim
Guggenheim
$55→$57
Buy
52.16%
Upside
Assigned
08/26/26
Amylyx price target raised to $57 from $55 at GuggenheimAmylyx price target raised to $57 from $55 at Guggenheim
LifeSci Capital Analyst forecast on AMLX
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$24→$44
Buy
17.46%
Upside
Reiterated
08/22/26
Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital
H.C. Wainwright Analyst forecast on AMLX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$34→$55
Buy
46.82%
Upside
Reiterated
08/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mizuho Securities Analyst forecast on AMLX
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$30→$42
Buy
12.12%
Upside
Reiterated
08/19/26
Mizuho Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)
Citi Analyst forecast on AMLX
Geoff Meacham
Citi
Citi
$26→$32
Buy
-14.58%
Downside
Reiterated
08/19/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Insight Molecular Diagnostics (NASDAQ: IMDX) and Innovent Biologics (Other OTC: IVBXF)
Bank of America Securities Analyst forecast on AMLX
Jason Gerberry
Bank of America Securities
Bank of America Securities
$39
Buy
4.11%
Upside
Reiterated
08/18/26
Jason Gerberry Boosts Amylyx Price Target to $39 on Strong LUCIDITY Phase 3 Avexitide Data and $1.8B Peak Sales Outlook
TD Cowen Analyst forecast on AMLX
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/18/26
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Moderna (NASDAQ: MRNA) and Merck & Company (NYSE: MRK)
Stifel Nicolaus Analyst forecast on AMLX
James Condulis
Stifel Nicolaus
Stifel Nicolaus
―
Buy
―
Reiterated
08/18/26
Analysts' Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), BioMarin Pharmaceutical (BMRN)
Robert W. Baird Analyst forecast on AMLX
Christopher Chen
Robert W. Baird
Robert W. Baird
$28→$52
Buy
38.81%
Upside
Reiterated
08/18/26
Amylyx price target raised to $52 from $28 at BairdAmylyx price target raised to $52 from $28 at Baird
Goldman Sachs Analyst forecast on AMLX
Corinne Johnson
Goldman Sachs
Goldman Sachs
$22→$23
Buy
-38.60%
Downside
Reiterated
06/18/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and AbCellera Biologics (NASDAQ: ABCL)
Leerink Partners Analyst forecast on AMLX
Marc Goodman
Leerink Partners
Leerink Partners
$10→$20
Buy
-46.61%
Downside
Reiterated
10/07/25
Leerink Partners Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
BLTEBelite Bio, Inc. ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amylyx Pharmaceuticals Inc

3 Months
Andrew FeinH.C. Wainwright
Success Rate
15/22 ratings generated profit
68%
Average Return
+44.14%
Copying Andrew Fein's trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +44.14% per trade.
1 Year
Andrew FeinH.C. Wainwright
Success Rate
22/22 ratings generated profit
100%
Average Return
+162.50%
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +162.50% per trade.
2 Years
Andrew FeinH.C. Wainwright
Success Rate
22/22 ratings generated profit
100%
Average Return
+420.87%
Copying Andrew Fein's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +420.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMLX Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
15
10
10
7
3
Buy
13
8
7
18
17
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
18
17
25
20
In the current month, AMLX has received 20 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AMLX average Analyst price target in the past 3 months is 43.00.
Each month's total comprises the sum of three months' worth of ratings.

AMLX Financial Forecast

AMLX Earnings Forecast

Next quarter’s earnings estimate for AMLX is -$0.38 with a range of -$0.43 to -$0.33. The previous quarter’s EPS was -$0.39. AMLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AMLX has Performed in-line its overall industry.
Next quarter’s earnings estimate for AMLX is -$0.38 with a range of -$0.43 to -$0.33. The previous quarter’s EPS was -$0.39. AMLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AMLX has Performed in-line its overall industry.

AMLX Sales Forecast

Next quarter’s sales forecast for AMLX is $59.00K with a range of $0.00 to $416.00K. The previous quarter’s sales results were $0.00. AMLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AMLX has Performed in-line its overall industry.
Next quarter’s sales forecast for AMLX is $59.00K with a range of $0.00 to $416.00K. The previous quarter’s sales results were $0.00. AMLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AMLX has Performed in-line its overall industry.

AMLX Stock Forecast FAQ

What is AMLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Amylyx Pharmaceuticals Inc’s 12-month average price target is 43.00.
    What is AMLX’s upside potential, based on the analysts’ average price target?
    Amylyx Pharmaceuticals Inc has 14.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AMLX a Buy, Sell or Hold?
          Amylyx Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Amylyx Pharmaceuticals Inc’s price target?
            The average price target for Amylyx Pharmaceuticals Inc is 43.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $57.00 ,the lowest forecast is $23.00. The average price target represents 14.79% Increase from the current price of $37.46.
              What do analysts say about Amylyx Pharmaceuticals Inc?
              Amylyx Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of AMLX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.